

Rajwanth Veluswamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1111902/publications.pdf>

Version: 2024-02-01

13
papers

137
citations

1684188

5
h-index

1372567

10
g-index

14
all docs

14
docs citations

14
times ranked

182
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status. JNCI Cancer Spectrum, 2022, 6, .	2.9	2
2	Real-World longitudinal practice patterns in the use of PD-1 and PD-L1 inhibitors as First-Line therapy in patients with Non-Small cell lung cancer in the United States. Cancer Medicine, 2022, , .	2.8	2
3	Small cell lung cancer patients treated with immune checkpoint inhibitor: a systematic literature review of treatment efficacy, safety and quality of life. Current Medical Research and Opinion, 2022, 38, 1361-1368.	1.9	4
4	A phase 1b/2 trial of dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC.. Journal of Clinical Oncology, 2022, 40, TPS9139-TPS9139.	1.6	2
5	Treatment patterns and outcomes in resectable early stage NSCLC: Interim analysis of a global real-world study.. Journal of Clinical Oncology, 2022, 40, e18803-e18803.	1.6	1
6	Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality. ERJ Open Research, 2021, 7, 00018-2021.	2.6	5
7	Effect of first-line pembrolizumab treatment in individuals with advanced non-small cell lung cancer and poor performance status.. Journal of Clinical Oncology, 2021, 39, e18796-e18796.	1.6	0
8	Radical surgery in malignant pleural mesothelioma (MPM): An analysis of SEER database.. Journal of Clinical Oncology, 2021, 39, 8554-8554.	1.6	0
9	KRAS G12C Mutant Non-Small Cell Lung Cancer. Journal of Molecular Diagnostics, 2021, 23, 507-520.	2.8	40
10	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. Oncologist, 2021, 26, e1226-e1239.	3.7	17
11	PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research, 2020, 9, 1343-1360.	2.8	22
12	Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis. Oncotarget, 2019, 10, 7142-7155.	1.8	42
13	Does race affect the quality of treatment for intermediate-risk and high-risk prostate cancer?. Journal of Clinical Oncology, 2014, 32, e17678-e17678.	1.6	0